Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats

Alan H. Cohen, Kimberly Hanson, Ken Morris, Brian Fouty, Ivan F. McMurtry, William Clarke, David M. Rodman

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

While it is known that nitric oxide (NO) is an important modulator of tone in the hypertensive pulmonary circulation, the roles of cyclic 3′-5′-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain. We found that isolated lung perfusate levels of cGMP were over ninefold elevated in hypertensive vs. normotensive control rats. 98-100% of lung cGMP hydrolytic activity was cGMP-specific PDE5, with no significant decrease in PDE activity in hypertensive lungs, suggesting that the elevation in cGMP was due to accelerated production rather than reduced degradation. In pulmonary hypertensive rat lungs, in vitro, cGMP-PDE inhibition by E4021[1-(6-chloro-4-(3,4-methylbenzyl) amino-quinazolin-2-yl)piperdine-4-carboxylate], increased perfusate cGMP threefold, reduced hypoxic vasoconstriction by 58±2%, and reduced baseline pulmonary artery pressure by 37±5%. In conscious, pulmonary hypertensive rats, intravenous administration of E4021 reduced hypoxic vasoconstriction by 68±8%, pulmonary artery pressure by 12.6±3.7% and total pulmonary resistance by 13.1±6.4%, with no significant effect on cardiac output, systemic pressure, and resistance. Comparison of E4021 to inhaled nitric oxide demonstrated that cGMP-PDE inhibition was as selective and as effective as inhaled NO.

Original languageEnglish (US)
Pages (from-to)172-179
Number of pages8
JournalJournal of Clinical Investigation
Volume97
Issue number1
DOIs
StatePublished - Jan 1 1996

Fingerprint

Pulmonary Circulation
Phosphoric Diester Hydrolases
Lung
Nitric Oxide
Vasoconstriction
Pressure
Pulmonary Artery
3'-guanylic acid
Intravenous Administration
Cardiac Output

Keywords

  • Cyclic GMP
  • E4021
  • Endothelial-derived relaxing factor
  • Nitric oxide
  • Zaprinast

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats. / Cohen, Alan H.; Hanson, Kimberly; Morris, Ken; Fouty, Brian; McMurtry, Ivan F.; Clarke, William; Rodman, David M.

In: Journal of Clinical Investigation, Vol. 97, No. 1, 01.01.1996, p. 172-179.

Research output: Contribution to journalArticle

Cohen, Alan H. ; Hanson, Kimberly ; Morris, Ken ; Fouty, Brian ; McMurtry, Ivan F. ; Clarke, William ; Rodman, David M. / Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats. In: Journal of Clinical Investigation. 1996 ; Vol. 97, No. 1. pp. 172-179.
@article{413b17328a4047a882366fd45af32a74,
title = "Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats",
abstract = "While it is known that nitric oxide (NO) is an important modulator of tone in the hypertensive pulmonary circulation, the roles of cyclic 3′-5′-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain. We found that isolated lung perfusate levels of cGMP were over ninefold elevated in hypertensive vs. normotensive control rats. 98-100{\%} of lung cGMP hydrolytic activity was cGMP-specific PDE5, with no significant decrease in PDE activity in hypertensive lungs, suggesting that the elevation in cGMP was due to accelerated production rather than reduced degradation. In pulmonary hypertensive rat lungs, in vitro, cGMP-PDE inhibition by E4021[1-(6-chloro-4-(3,4-methylbenzyl) amino-quinazolin-2-yl)piperdine-4-carboxylate], increased perfusate cGMP threefold, reduced hypoxic vasoconstriction by 58±2{\%}, and reduced baseline pulmonary artery pressure by 37±5{\%}. In conscious, pulmonary hypertensive rats, intravenous administration of E4021 reduced hypoxic vasoconstriction by 68±8{\%}, pulmonary artery pressure by 12.6±3.7{\%} and total pulmonary resistance by 13.1±6.4{\%}, with no significant effect on cardiac output, systemic pressure, and resistance. Comparison of E4021 to inhaled nitric oxide demonstrated that cGMP-PDE inhibition was as selective and as effective as inhaled NO.",
keywords = "Cyclic GMP, E4021, Endothelial-derived relaxing factor, Nitric oxide, Zaprinast",
author = "Cohen, {Alan H.} and Kimberly Hanson and Ken Morris and Brian Fouty and McMurtry, {Ivan F.} and William Clarke and Rodman, {David M.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1172/JCI118386",
language = "English (US)",
volume = "97",
pages = "172--179",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats

AU - Cohen, Alan H.

AU - Hanson, Kimberly

AU - Morris, Ken

AU - Fouty, Brian

AU - McMurtry, Ivan F.

AU - Clarke, William

AU - Rodman, David M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - While it is known that nitric oxide (NO) is an important modulator of tone in the hypertensive pulmonary circulation, the roles of cyclic 3′-5′-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain. We found that isolated lung perfusate levels of cGMP were over ninefold elevated in hypertensive vs. normotensive control rats. 98-100% of lung cGMP hydrolytic activity was cGMP-specific PDE5, with no significant decrease in PDE activity in hypertensive lungs, suggesting that the elevation in cGMP was due to accelerated production rather than reduced degradation. In pulmonary hypertensive rat lungs, in vitro, cGMP-PDE inhibition by E4021[1-(6-chloro-4-(3,4-methylbenzyl) amino-quinazolin-2-yl)piperdine-4-carboxylate], increased perfusate cGMP threefold, reduced hypoxic vasoconstriction by 58±2%, and reduced baseline pulmonary artery pressure by 37±5%. In conscious, pulmonary hypertensive rats, intravenous administration of E4021 reduced hypoxic vasoconstriction by 68±8%, pulmonary artery pressure by 12.6±3.7% and total pulmonary resistance by 13.1±6.4%, with no significant effect on cardiac output, systemic pressure, and resistance. Comparison of E4021 to inhaled nitric oxide demonstrated that cGMP-PDE inhibition was as selective and as effective as inhaled NO.

AB - While it is known that nitric oxide (NO) is an important modulator of tone in the hypertensive pulmonary circulation, the roles of cyclic 3′-5′-guanosine monophosphate (cGMP) and cGMP-phosphodiesterase (PDE) are uncertain. We found that isolated lung perfusate levels of cGMP were over ninefold elevated in hypertensive vs. normotensive control rats. 98-100% of lung cGMP hydrolytic activity was cGMP-specific PDE5, with no significant decrease in PDE activity in hypertensive lungs, suggesting that the elevation in cGMP was due to accelerated production rather than reduced degradation. In pulmonary hypertensive rat lungs, in vitro, cGMP-PDE inhibition by E4021[1-(6-chloro-4-(3,4-methylbenzyl) amino-quinazolin-2-yl)piperdine-4-carboxylate], increased perfusate cGMP threefold, reduced hypoxic vasoconstriction by 58±2%, and reduced baseline pulmonary artery pressure by 37±5%. In conscious, pulmonary hypertensive rats, intravenous administration of E4021 reduced hypoxic vasoconstriction by 68±8%, pulmonary artery pressure by 12.6±3.7% and total pulmonary resistance by 13.1±6.4%, with no significant effect on cardiac output, systemic pressure, and resistance. Comparison of E4021 to inhaled nitric oxide demonstrated that cGMP-PDE inhibition was as selective and as effective as inhaled NO.

KW - Cyclic GMP

KW - E4021

KW - Endothelial-derived relaxing factor

KW - Nitric oxide

KW - Zaprinast

UR - http://www.scopus.com/inward/record.url?scp=0030070656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030070656&partnerID=8YFLogxK

U2 - 10.1172/JCI118386

DO - 10.1172/JCI118386

M3 - Article

C2 - 8550830

AN - SCOPUS:0030070656

VL - 97

SP - 172

EP - 179

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -